Assessing Sarepta Therapeutics: Insights From 12 Financial Analysts
In the preceding three months, 12 analysts have released ratings for Sarepta Therapeutics (NASDAQ:SRPT), presenting a wide array…
Sarepta Therapeutics’ Next-Gen Duchenne Muscular Therapy Shows Efficacy At Less Frequent Dosing
Sarepta Therapeutics unveils results from MOMENTUM study's Phase 2 trial for SRP-5051, a next-gen PPMO treatment targeting Duchenne muscular dystrophy.
Sarepta Therapeutics Announces Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive data from Part B of the MOMENTUM study (Study SRP-5051-201), a global, Phase 2,
A Closer Look at 14 Analyst Recommendations For Sarepta Therapeutics
Sarepta Therapeutics (NASDAQ:SRPT) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from…
Stocks Flip To Losses, Nvidia Defies Gravity, Bitcoin Pauses For A Breather: What’s Driving Markets Tuesday?
Tuesday on Wall Street was marked by a subdued trend in major equity indices as investors remained cautious ahead of key inflation data scheduled for release on Thursday and the kick-off of the earnings season.
Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year
Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) reported preliminary FY23 net product
Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday.
Sarepta Therapeutics Reports Preliminary Q4 Net Product Revenue For ELEVIDYS Are Expected To Be ~$131.3M And $200.4M For FY23; Preliminary Total Net Product Revenue Is Expected To Total $1.145B For FY23
– Preliminary total net product revenue is expected to total $1.145 billion for full-year 2023– Preliminary ELEVIDYS net product revenue is expected to be $131.3 million for the fourth quarter and $200.4 million for
5 Biotech Stocks That Should Be On Investors’ Radar As JPMorgan Healthcare Conference Gets Underway Monday
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List – Potential Room For Growth In 2024
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction List.